Journal · Updated 2026-08-11
Strut Health Review 2026: The $99 Entry That Can't Be Ranked, Explained
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
Short answer — August 2026
Strut Health owns the market's most eye-catching entries — sublingual semaglutide from ninety-nine dollars, injectable from one forty-nine, tirzepatide injectable from one ninety-nine — every one an auto-refill "starting at" price for the lowest dose, with no published maintenance-dose rate, which is precisely the dose-anchored structure methodology §4 records without ranking. Two more structural facts from our captures: the oral/sublingual formats are conditioned — the tirzepatide lozenge requires that an injectable GLP-1 failed or can't be used — and the sublingual route itself carries the unproven-absorption caveat from our oral guide. The review, therefore, is mostly a question: what does month six cost? — and Strut's public pages don't say.
Why start-only pricing can't be compared
A starting price describes month one at the smallest dose; a program's cost is what maintenance runs — and the gap between the two is exactly where dose-anchored programs make their margin, which is why our tables refuse the comparison rather than guessing it. Against published-maintenance programs the contrast is direct: bmiMD's one twenty-nine is one twenty-nine at every dose; Strut's one forty-nine is one forty-nine at the entry dose and unknown at yours. The auto-refill mechanic compounds the caution: escalations that reprice inside a subscription are the pattern to interrogate before the card number, not after. And the conditioned-lozenge structure is worth reading straight — a format offered only after injectable failure is positioned as a fallback by its own terms.
What would move the row, and verdict
Three answers in writing: the maintenance-dose price for each format; the escalation mechanics (when the price changes and to what); the pharmacy name. Land those — via your intake screenshots or our capture file — and Strut becomes rankable, possibly competitively. Until then the verdict is the methodology's: recorded, labeled, and behind every program whose maintenance number is public — because in this market, the number you can't see is the number.
Questions people ask
How much does Strut Health really cost?
Publicly: 'starting at' $99 (sublingual semaglutide), $149 (injectable semaglutide), $199 (injectable tirzepatide) — lowest-dose auto-refill entry prices. The maintenance-dose price isn't published, which is why our rankings record Strut without placing it. Get your dose's ongoing rate in writing before subscribing.
Why isn't Strut in your cheapest lists despite the $99 price?
Methodology §4: start-only, dose-anchored figures aren't rankable — $99 describes month one at the smallest dose, not the program's cost. Programs are ranked on all-in maintenance pricing; Strut's is unpublished.
What's the catch with Strut's tirzepatide lozenge?
Two: it's offered only if an injectable GLP-1 failed or can't be used (a conditional fallback by its own terms), and sublingual/lozenge GLP-1 absorption has no approved product or pivotal trial behind it. Evaluate it as an unverified route, not a needle-free equivalent.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.